Aquestive Therapeutics, Inc. (AQST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 25M 50M 75M FY17: 66.9M FY18: 67.4M FY19: 52.6M FY20: 45.8M FY21: 50.8M FY22: 47.7M FY23: 50.6M FY24: 57.6M FY25: 44.5M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 15M 30M 45M FY19: 32.2M FY20: 32.9M FY22: 28.3M FY23: 29.8M FY24: 39.7M FY25: 26M FY19 FY20 FY22 FY23 FY24 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-75M -50M -25M 0 25M 50M 75M FY17: -113K FY18: -48.9M FY19: -52.7M FY20: -42.9M FY21: -34.7M FY22: -42.1M FY23: -15.1M FY24: -30.8M FY25: -71.1M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-90M -60M -30M 0 30M 60M 90M FY17: -8.9M FY18: -61.4M FY19: -66.2M FY20: -55.8M FY21: -70.5M FY22: -54.4M FY23: -7.9M FY24: -44.1M FY25: -83.8M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 8M 16M 24M FY19: 20.4M FY20: 13M FY22: 19.4M FY23: 20.8M FY24: 17.9M FY25: 18.6M FY19 FY20 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-75M -50M -25M 0 25M 50M 75M FY17: 5.8M FY18: -13M FY19: -60.2M FY20: -45.5M FY21: -33M FY22: -9.8M FY23: -6.4M FY24: -35.8M FY25: -52.4M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-75M -50M -25M 0 25M 50M 75M FY17: 3.8M FY18: -14.8M FY19: -60.9M FY20: -46M FY21: -33.9M FY22: -10.8M FY23: -7.4M FY24: -35.9M FY25: -53M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 40M 80M 120M FY20: 33.7M FY21: 38.1M FY22: 48.7M FY23: 61.3M FY24: 86.7M FY25: 106.9M FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '18: -2.83 Q1 '19: -3.69 Q2 '19: -2.61 Q3 '19: -2.71 Q4 '19: -2.63 Q1 '20: -2.53 Q2 '20: -1.78 Q3 '20: -1.53 Q4 '20: -1.66 Q1 '21: -1.58 Q2 '21: -1.84 Q3 '21: -1.72 Q4 '21: -1.84 Q1 '22: -1.75 Q2 '22: -1.78 Q3 '22: -1.64 Q4 '22: -1.13 Q1 '23: -0.70 Q2 '23: -0.44 Q3 '23: -0.24 Q4 '23: -0.15 Q1 '24: -0.43 Q2 '24: -0.36 Q3 '24: -0.46 Q4 '24: -0.52 Q1 '25: -0.59 Q2 '25: -0.70 Q3 '25: -0.71 Q4 '25: -0.79 Q1 '26: -0.62 Q2 '26: -0.66 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.